New Jersey District Court Limits Actavis To Cash Payments

This article is part of a Chronicle. See more from this Chronicle

Donald Falk, Christopher Kelly, Apr 29, 2014

As with patent infringement litigation in many industries, innovator pharmaceutical companies frequently settle their patent infringement litigation against would-be generic challengers by licensing the alleged infringer to market its generic version of the patented drug before patent expiration. But because generic entry costs an innovator firm far more than it profits the entrant, a l